S.A. Protsenko (1), A.I. Semenova (1), A.P. Oganesyan (1), E.M. Anokhina (1), A.V. Novik (1, 2)1) N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; 2) St. Petersburg State Pediatric Medical University, St. Petersburg, Russia
Currently, the introduction of immune checkpoint inhibitors into the clinical practice as a drug therapy for patients with metastatic renal cell carcinoma (mRCC) has significantly improved treatment outcomes, primarily overall survival, and has also identified new challenges for continuing research in this area. Recently, a number of clinical trials have been conducted to study combinations of immuno-oncological drugs, both among themselves and in combination with targeted therapy, which is likely to serve as a basis for creating other standards of treatment in the future. This review demonstrates the results of randomized phase III studies, which allowed to define modern standards in the treatment of mRCC. Also, the own authors’ experience of using the first immune-oncological drug nivoluumab registered for disseminated kidney cancer is presented. This PD-1 inhibitor was used in the framework of the CA209254 expanded access program as a second-line drug therapy for mRCC patients who had progression of the disease after targeted therapy with antiangiogenic drugs.
For citations: Protsenko S.A., Semenova A.I., Oganesyan A.P., Anokhina E.M., Novik A.V. Modern immunotherapy for kidney cancer. Farmateka. 2019;26(7):73–78. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.7.73-78
Corresponding author: Аnna I. Semenova, PhD, Oncologist, Department of Chemotherapy and Innovative Technologies, Senior Reseracher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; e-mail: firstname.lastname@example.org
Address: 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation